KR880700060A - 고수율의 활성인자 ix의 제조방법 - Google Patents

고수율의 활성인자 ix의 제조방법

Info

Publication number: KR880700060A
Authority: KR; South Korea
Prior art keywords: pct; manufacturing; active factor; high yield; date
Prior art date: 1985-04-22

Application number

KR860700914A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-22

Filing date

1986-12-22

Publication date

1988-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24914546&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880700060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1986-12-22 Application filed filed Critical

1988-02-15 Publication of KR880700060A publication Critical patent/KR880700060A/ko

Links

102100022641 Coagulation factor IX Human genes 0.000 title abstract 3
108010076282 Factor IX Proteins 0.000 title abstract 3
229960004222 factor ix Drugs 0.000 title abstract 3
238000004519 manufacturing process Methods 0.000 title 1
229930003448 Vitamin K Natural products 0.000 abstract 1
210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 abstract 1
238000012258 culturing Methods 0.000 abstract 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract 1
235000019168 vitamin K Nutrition 0.000 abstract 1
239000011712 vitamin K Substances 0.000 abstract 1
150000003721 vitamin K derivatives Chemical class 0.000 abstract 1
229940046010 vitamin k Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

KR860700914A 1985-04-22 1986-12-22 고수율의 활성인자 ix의 제조방법 KR880700060A (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72543685A	1985-04-22	1985-04-22
PCT/US1986/000817 WO1986006408A1 (en)	1985-04-22	1986-04-17	HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX

Publications (1)

Publication Number	Publication Date
KR880700060A true KR880700060A (ko)	1988-02-15

Family

ID=24914546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR860700914A KR880700060A (ko)	1985-04-22	1986-12-22	고수율의 활성인자 ix의 제조방법

Country Status (8)

Country	Link
US (1)	US4770999A (ko)
EP (1)	EP0218713B1 (ko)
JP (1)	JP2584443B2 (ko)
KR (1)	KR880700060A (ko)
AT (1)	ATE74164T1 (ko)
AU (1)	AU5864086A (ko)
DE (1)	DE3684546D1 (ko)
WO (1)	WO1986006408A1 (ko)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775624A (en) *	1985-02-08	1988-10-04	Eli Lilly And Company	Vectors and compounds for expression of human protein C
US5171569A (en) *	1985-03-15	1992-12-15	National Research Development Corporation	Factor IX preparations uncontaminated by plasma components or pox virus
US5516650A (en) *	1985-06-27	1996-05-14	Zymogenetics, Inc.	Production of activated protein C
US4959318A (en) *	1985-06-27	1990-09-25	Zymogenetics, Inc.	Expression of protein C
EP0245949B1 (en) *	1986-04-09	1997-10-29	Eli Lilly And Company	A method of using eukaryotic expression vectors comprising the bk virus enhancer
FR2599752B1 (fr) *	1986-06-10	1989-11-03	Transgene Sa	Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2600334B1 (fr) *	1986-06-23	1989-05-12	Transgene Sa	Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US5082774A (en) *	1988-08-30	1992-01-21	The General Hospital Corporation	Recombinant human nerve growth factor
FR2638643B1 (fr) *	1988-11-09	1991-04-12	Transgene Sa	Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5047335A (en) *	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
US5225537A (en) *	1989-12-29	1993-07-06	Zymogenetics, Inc.	Methods for producing hybrid phospholipid-binding proteins
DE69131292T2 (de) *	1990-01-29	1999-09-30	Zymogenetics, Inc.	Antikoagulierende proteine
ES2109336T3 (es) *	1990-11-26	1998-01-16	Genetics Inst	Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
US5817788A (en) *	1991-02-28	1998-10-06	Zymogenetics, Inc.	Modified factor VII
US5997864A (en)	1995-06-07	1999-12-07	Novo Nordisk A/S	Modified factor VII
US5788965A (en) *	1991-02-28	1998-08-04	Novo Nordisk A/S	Modified factor VII
US5861374A (en) *	1991-02-28	1999-01-19	Novo Nordisk A/S	Modified Factor VII
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
DE69231401T2 (de) *	1991-03-01	2001-02-08	Rhone-Poulenc Rorer International (Holdings) Inc., Greenville	Herstellung von faktor-ix
US6039944A (en) *	1992-02-28	2000-03-21	Zymogenetics, Inc.	Modified Factor VII
US6372716B1 (en)	1994-04-26	2002-04-16	Genetics Institute, Inc.	Formulations for factor IX
AT403167B (de) *	1994-11-14	1997-11-25	Immuno Ag	Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5770700A (en) *	1996-01-25	1998-06-23	Genetics Institute, Inc.	Liquid factor IX formulations
US6475725B1 (en) *	1997-06-20	2002-11-05	Baxter Aktiengesellschaft	Recombinant cell clones having increased stability and methods of making and using the same
SI1266006T1 (sl) *	2000-03-22	2006-06-30	Octagene Gmbh	Proizvodnja rekombinantnih muteinov krvnega koagulacijskega faktorja VIII v humanih celicnih linijah
AU2002225681A1 (en) *	2000-11-15	2002-05-27	Globe Immune, Inc.	Yeast-dentritic cell vaccines and uses thereof
EP1418810A4 (en)	2001-08-03	2006-08-02	Us Gov Health & Human Serv	TREATMENT OF HEMOPHILIA ORAL
AU2004236174B2 (en)	2001-10-10	2011-06-02	Novo Nordisk A/S	Glycopegylation methods and proteins/peptides produced by the methods
NZ532027A (en)	2001-10-10	2008-09-26	Neose Technologies Inc	Remodeling and glycoconjugation of peptides
EP2305313B1 (en)	2001-10-10	2014-03-26	ratiopharm GmbH	Remodelling and glycoconjugation of interferon-alpha (IFNa)
ES2339710T5 (es)	2003-09-23	2017-10-05	University Of North Carolina At Chapel Hill	Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
JP5037331B2 (ja) *	2004-03-19	2012-09-26	バクスター・インターナショナル・インコーポレイテッド	出血性障害の処置のための第ｉｘａ因子
AU2005260763B2 (en) *	2004-06-30	2011-12-22	Nektar Therapeutics	Polymer-factor IX moiety conjugates
EP1861499A4 (en)	2005-03-15	2008-09-03	Univ North Carolina	METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ACTIVE PROTEINS DEPENDENT ON VITAMIN K
EP1707634A1 (en)	2005-03-29	2006-10-04	Octapharma AG	Method for isolation of recombinantly produced proteins
EP2975135A1 (en)	2005-05-25	2016-01-20	Novo Nordisk A/S	Glycopegylated factor IX
US20080045453A1 (en) *	2005-12-21	2008-02-21	Drohan William N	Method of producing biologically active vitamin K dependent proteins by recombinant methods
EP2423305A1 (en)	2006-06-19	2012-02-29	Catalyst Biosciences, Inc.	Modified coagulation factor IX polypeptides and use thereof for treatment
EP2451963B1 (en) *	2009-07-10	2014-04-30	CSL Limited	Method of increasing the expression yield of vitamin k-dependent proteins
CA2772051C (en)	2009-08-24	2020-08-18	Amunix Operating Inc.	Coagulation factor ix compositions and methods of making and using same
WO2011095604A1 (en)	2010-02-04	2011-08-11	Octapharma Biopharmaceuticals Gmbh	Half-life prolongation of proteins
PT2616090T (pt)	2010-09-17	2023-10-16	Takeda Pharmaceuticals Co	Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro
ES2556454T3 (es)	2010-10-05	2016-01-18	Novo Nordisk Health Care Ag	Proceso para producción de proteínas
WO2012088222A2 (en)	2010-12-21	2012-06-28	The University Of North Carolina At Chapel Hill	Methods and compositions for producing active vitamin k-dependent proteins
EP3549953A1 (en)	2012-02-15	2019-10-09	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
EP2814840B1 (en)	2012-02-15	2019-11-13	Bioverativ Therapeutics Inc.	Factor viii compositions and methods of making and using same
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
WO2017024060A1 (en)	2015-08-03	2017-02-09	Biogen Ma Inc.	Factor ix fusion proteins and methods of making and using same
CA3044574A1 (en)	2016-11-23	2018-05-31	Bioverativ Therapeutics Inc.	Bispecific antibodies binding to coagulation factor ix and coagulation factor x
MX2019006444A (es)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2020505424A (ja)	2017-01-31	2020-02-20	バイオベラティブセラピューティクスインコーポレイテッド	因子ｉｘ融合タンパク質ならびにその製造および使用方法
JP7209298B2 (ja)	2017-03-31	2023-01-20	公立大学法人奈良県立医科大学	血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
EP3617316A4 (en)	2017-04-27	2020-12-23	Chugai Seiyaku Kabushiki Kaisha	COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
KR20200035130A (ko)	2017-08-09	2020-04-01	바이오버라티브 테라퓨틱스 인크.	핵산 분자 및 이의 용도
TW202015723A (zh)	2018-05-18	2020-05-01	美商百歐維拉提夫治療公司	治療ａ型血友病的方法
WO2020033863A1 (en)	2018-08-09	2020-02-13	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof for non-viral gene therapy
US20200289628A1 (en)	2018-10-18	2020-09-17	Intellia Therapeutics, Inc.	Compositions and methods for expressing factor ix

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2625412B2 (ja) *	1982-08-04	1997-07-02	ブリティッシュ・テクノロジー・グループ・リミテッド	ヒト第９因子ポリペプチドをコードするｃｄｎａ
GB2125409B (en) *	1982-08-04	1985-11-13	Nat Res Dev	Genetic engineering
FR2564106B1 (fr) *	1984-05-09	1988-04-22	Transgene Sa	Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
WO1985005376A1 (fr) *	1984-05-22	1985-12-05	Transgene S.A.	Vecteurs d'expression du facteur ix et lignees cellulaires produisant le facteur ix actif
US4775624A (en) *	1985-02-08	1988-10-04	Eli Lilly And Company	Vectors and compounds for expression of human protein C
DE3688983T2 (de) *	1985-03-15	1994-02-17	British Tech Group	Faktor IX-Protein.
GR860984B (en) *	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells

1986
- 1986-04-17 US US06/929,294 patent/US4770999A/en not_active Expired - Lifetime
- 1986-04-17 DE DE8686902988T patent/DE3684546D1/de not_active Expired - Lifetime
- 1986-04-17 AU AU58640/86A patent/AU5864086A/en not_active Abandoned
- 1986-04-17 AT AT86902988T patent/ATE74164T1/de not_active IP Right Cessation
- 1986-04-17 WO PCT/US1986/000817 patent/WO1986006408A1/en active IP Right Grant
- 1986-04-17 JP JP61502661A patent/JP2584443B2/ja not_active Expired - Lifetime
- 1986-04-17 EP EP86902988A patent/EP0218713B1/en not_active Expired - Lifetime
- 1986-12-22 KR KR860700914A patent/KR880700060A/ko not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0218713A1 (en)	1987-04-22
EP0218713B1 (en)	1992-03-25
EP0218713A4 (en)	1987-04-28
US4770999A (en)	1988-09-13
ATE74164T1 (de)	1992-04-15
WO1986006408A1 (en)	1986-11-06
AU5864086A (en)	1986-11-18
DE3684546D1 (de)	1992-04-30
JPS62502514A (ja)	1987-10-01
JP2584443B2 (ja)	1997-02-26

Legal Events

Date	Code	Title	Description
1991-12-22	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid

Publication	Publication Date	Title
KR880700060A (ko)	1988-02-15	고수율의 활성인자 ix의 제조방법
ES2007341A6 (es)	1989-06-16	Un procedimiento para producir m-csf
IT8520869A0 (it)	1985-05-24	Procedimento di fermentazione per produrre acido ialuronico.
ATE46906T1 (de)	1989-10-15	Verfahren zur herstellung von 5,6,7,8-tetrahydro6-(l-erythro-1'-2'-dihydroxypropyl)pterin.
DE3775675D1 (de)	1992-02-13	Verfahren zur herstellung enantiomerenreiner r-(+)-alpha-liponsaeure und s-(-)-alpha-liponsaeure (thioctsaeure) sowie nonen- beziehungsweise mesylderivate als zwischenprodukte hierfuer.
SE8701934L (sv)	1987-11-13	Okad expression av humant interleukin-2 i deggdjursceller
ES8504195A1 (es)	1985-04-16	Procedimiento de preparar teofilinas 7-substituidas.
ES8603373A1 (es)	1986-01-01	Procedimiento de preparar acido (+)-2-(6-metoxi-2-naftil)- propionico
ES2077674T3 (es)	1995-12-01	Aumento de la produccion de proteinas en animales.
ATE44028T1 (de)	1989-06-15	Kronenaether-derivate.
DE3583245D1 (de)	1991-07-25	Herstellung von aminosaeuren durch biologischen austausch.
ES2026207T3 (es)	1992-04-16	Un procedimiento para preparar 4,4-isopropilidenditio-bis(2,6-di-t-butilfenol).
ES2040226T3 (es)	1993-10-16	Procedimiento para preparar nuevos tetrahidro-benzotiazoles.
ES2072296T3 (es)	1995-07-16	Metodo para preparar 2-fenilbenzotriazoles.
ATE73792T1 (de)	1992-04-15	Annaeherung zur herstellung von natuerlicher vitamin e verwendender asymetrischer synthese.
ES8706202A1 (es)	1987-06-01	Procedimiento para la obtencion de efomicinas a,b.c.d y f.
ATE58519T1 (de)	1990-12-15	Herstellung von trichlorphenol.
SU1468978A1 (ru)	1989-03-30	Катодный узел дл получени хрома
SE8700592D0 (sv)	1987-02-13	Novel process
ATE46315T1 (de)	1989-09-15	Verfahren zur herstellung optisch aktiver chinonderivate.
KR860003828A (ko)	1986-06-13	맥반의왕석을 함유하는 세안용 조성물
JPS5550473A (en)	1980-04-12	Production of ketones
SE7907942L (sv)	1980-03-27	Bromeringsforfarande
ES8403656A1 (es)	1984-03-16	Perfeccionamientos en un dispositivo para la purificacion del metal liquido de refrigeracion del nucleo de un reactor nuclear de neutrones rapidos.
DE3668166D1 (de)	1990-02-15	Verfahren zur herstellung von alkylarylethern.